Sivik Global Healthcare Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$7.74M |
| 2 |
UnitedHealth
UNH
|
+$7.22M |
| 3 |
Pfizer
PFE
|
+$6.28M |
| 4 |
Tenet Healthcare
THC
|
+$3.92M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$3.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVO
Novo Nordisk
NVO
|
+$7.06M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$6.08M |
| 3 |
Viatris
VTRS
|
+$4.25M |
| 4 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$4.14M |
| 5 |
Biogen
BIIB
|
+$3.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.08% |
| 2 | Energy | 0.72% |
| 3 | Utilities | 0% |
Similar funds
Sivik Global Healthcare's Q2 2019 Portfolio in Review
As of Q2 2019, Sivik Global Healthcare held 74 positions worth $414M, up 52% from $271M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Sivik Global Healthcare deployed $137M of net new capital in Q2 2019, opening 15 new positions and adding to 11 existing holdings. Its largest new stake was Becton Dickinson: 33,313 shares worth $8.19M.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 93% a quarter earlier, followed by Energy and Utilities.
On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $4.14M trimmed.
- Sivik Global Healthcare's largest Q2 2019 buy was Becton Dickinson: 33,313 shares worth $8.19M.
- Sivik Global Healthcare added most to Edwards Lifesciences in Q2 2019, an estimated $2.72M increase.
- Sivik Global Healthcare's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $4.14M.
- Sivik Global Healthcare fully exited Novo Nordisk in Q2 2019, selling an estimated $7.06M.
- Sivik Global Healthcare's ten largest holdings make up 55% of its $414M portfolio in Q2 2019.
- Sivik Global Healthcare opened 15 new positions and closed 14 in Q2 2019.
- Sivik Global Healthcare's portfolio value rose 52% quarter-over-quarter to $414M.
Based on Sivik Global Healthcare's 13F filing for Q2 2019, filed 14 Aug 2019.